Yinghui Li, Assistant Professor at Nanyang Technological University, shared a post on LinkedIn:
“Glad to see our latest work in RNA biology and nucleic acid therapeutics, published in Nature Communications!
Here, we identified a novel NF-kB-regulated long non-coding RNA, PLUM, in high-risk and VRD-refractory multiple myeloma patients that drives chemoresistance through its interaction with EZH2. We show PLUM-EZH2 interaction facilitates the formation of the PRC2 complex and enhances EZH2 activity. Through RNA structure prediction and in-silico docking of PLUM-EZH2 RNP complex, we designed novel antisense oligonucleotides (ASOs) which can disrupt PLUM-EZH2 interaction, in turn inhibiting EZH2 activity and the interaction of PRC2 core subunits. Functionally, our ASOs can disrupt the activity of EZH2, similar to FDA-approved inhibitor Tazemetostat, and abrogate the resistance of myeloma tumour cells to drugs used in the standard treatment regimen of multiple myeloma patients.
Provisional patent: 10202501192X
Warmest congratulations to postdoctoral fellow Kamalakshi Deka first author of this study, who also recently delivered her first baby in the lab!
Huge thanks to other lab members (past and present), Jean-Michel Carter, Akash Bahai, Daniel Aron Ang, and Nicholas Sim, as well as the invaluable support from our collaborators, Wee Joo Chng and Dennis Kappei.
We are grateful for the funding support of my earlier NRF fellowship, MOE Tier 1, and current NMRC OF-IRG grants.”
Title: Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
Journal: Nature Communications
Authors: Kamalakshi Deka, Jean-Michel Carter, Akash Bahai, Daniel Aron Ang, Nicholas Sim, Hooi Yan Chong, Guan Hwee Bernard Lee, Suet Mien Tan, Wee Joo Chng, Dennis Kappei, Yinghui Li
Wee Joo Chng, Vice President of Biomedical Science Research at the National University of Singapore and Group Director of Research Office at the National University Health System of Singapore, shared Yinghui Li’s post, adding:
“Another amazing work from Yinghui Li and her team.
Just very happy to have been able to contribute to this work!”
More posts featuring Wee Joo Chng on OncoDaily.